InflaRx ( (IFRX) ) just unveiled an announcement.
On March 20, 2025, InflaRx N.V. announced its financial results for 2024, highlighting significant achievements and future milestones. The company received European Commission approval for GOHIBIC® for treating SARS-CoV-2-induced ARDS and reached key recruitment milestones in its Phase 3 trial for vilobelimab in pyoderma gangrenosum. InflaRx also dosed the first patient in a Phase 2a trial for its oral C5aR inhibitor, INF904, with topline data expected in summer 2025. The company raised €28.7 million in February 2025, extending its cash runway into 2027, and aims to achieve several value inflection points, including interim analysis for vilobelimab and data readouts for INF904.
More about InflaRx
InflaRx N.V. is a biopharmaceutical company based in Jena, Germany, specializing in anti-inflammatory therapeutics that target the complement system. The company focuses on developing treatments for inflammatory diseases, with products such as GOHIBIC® (vilobelimab) and INF904, targeting conditions like SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and chronic spontaneous urticaria (CSU).
YTD Price Performance: -48.80%
Average Trading Volume: 360,511
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $81.23M
Find detailed analytics on IFRX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com